Avidity Partners Management’s Senti Biosciences Holdings SNTI Stock Holding History

Avidity Partners Management’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$4.93M	–	96
2022 Q1	$4.93M	Hold	50,000	–	–	0.1%	72
2021 Q4	$4.93M	Hold	50,000	–	–	0.1%	78
2021 Q3	$4.97M	Hold	50,000	–	–	0.11%	86
2021 Q2	$4.97M	Buy	+50,000	New	+$4.99M	0.13%	92

Other funds holding SNTI

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Intel Corp Santa Clara, California $621M AUM 34.06% 1-Year Est. Return

FMN

Financial Management Network Mission Viejo, California $697M AUM 21.37% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

Avidity Partners Management's SNTI Position: Q2 2022 in Review

Avidity Partners Management sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 50,000 shares — an estimated $4.93M sold.

Avidity Partners Management first reported a position in SNTI in Q2 2021 and held it in 4 quarters. The position peaked at $4.97M in Q3 2021. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

Avidity Partners Management reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
Avidity Partners Management sold 50,000 Senti Biosciences Holdings shares in Q2 2022, an estimated $4.93M.
Avidity Partners Management first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 4 quarters.
Avidity Partners Management's Senti Biosciences Holdings position peaked at $4.97M in Q3 2021.
22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.